Leukemia, B-Cell, Chronic Clinical Trial
Official title:
Observational Study for Evaluation of Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia.
300 patients, starting a new pharmacological treatment for B-CLL, were enrolled by 36 Italian Centres for assessing the Quality of Life (QoL). A descriptive analysis of QoL and the correlation of the age, sex, stage of disease, Time from first B-CLL diagnosis, Number of previous B-CLL treatments, reason of starting of the new B-CLL treatment: therapeutic Regimen, type of Centre, B-CLL treatment lasting, response to B-CLL treatment.
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been
renamed to Bayer Schering Pharma AG, Germany.
Bayer Schering Pharma AG, Germany is the sponsor of the trial.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00546793 -
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
|
Phase 1/Phase 2 | |
| Completed |
NCT00078520 -
Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells
|
Phase 1 | |
| Completed |
NCT00559624 -
Safety and Tolerability Open Label Dose Escalation Study of Acadesine in B-CLL Patients
|
Phase 1/Phase 2 | |
| Completed |
NCT00419250 -
A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
|
Phase 1 |